Rapport Therapeutics, Inc. RAPP Stock Issuance Proceeds
Stock Issuance Proceeds at other companies
Other financials
Where this comes from
Reported directly by Rapport Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromStockOptionsExercised.
The official record: Rapport Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Rapport Therapeutics, Inc.'s stock issuance proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Rapport Therapeutics, Inc.'s stock issuance proceeds?
- Rapport Therapeutics, Inc. (RAPP) reported stock issuance proceeds of $809K in Q1 2026.
- How has Rapport Therapeutics, Inc.'s stock issuance proceeds changed year-over-year?
- Rapport Therapeutics, Inc.'s stock issuance proceeds increased by 13383.3% year-over-year, from $6K to $809K.
- What is the long-term trend for Rapport Therapeutics, Inc.'s stock issuance proceeds?
- Over 2 years (2023 to 2025), Rapport Therapeutics, Inc.'s stock issuance proceeds has grown at a 399.6% compound annual growth rate (CAGR), from $54K to $1.35M.
- What does stock issuance proceeds mean?
- Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.